Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Clinical Trial ID NCT01701674

Rank	Title	Journal	Year	PubWeight™‹?›
1	At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.	J Leukoc Biol	2013	1.90
2	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2013	1.31
3	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.	Oncoimmunology	2014	1.22
4	Trial Watch: Adoptive cell transfer for anticancer immunotherapy.	Oncoimmunology	2013	0.95
5	Checkpoint modulation in melanoma: an update on ipilimumab and future directions.	Curr Oncol Rep	2013	0.94
6	Common gamma chain cytokines in combinatorial immune strategies against cancer.	Immunol Lett	2015	0.91
7	Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells.	Front Oncol	2014	0.85
8	Targeting CD8+ T-cell tolerance for cancer immunotherapy.	Immunotherapy	2014	0.81
9	New developments in the management of advanced melanoma - role of pembrolizumab.	Onco Targets Ther	2015	0.77
10	Melanoma immunotherapy.	Cancer Biol Ther	2014	0.76
11	Update on use of aldesleukin for treatment of high-risk metastatic melanoma.	Immunotargets Ther	2015	0.76
12	Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy.	Clin Cancer Res	2016	0.75